Selank
A synthetic tuftsin analog studied for anxiolytic, nootropic, and immune-modulating effects. Selank is researched for its influence on GABA and serotonergic systems without the sedation associated with benzodiazepine-class compounds.
Calm, without the trade-offs.
Selank is a synthetic heptapeptide developed in the 1990s by researchers at Russia’s Institute of Molecular Genetics, built from the endogenous immunomodulatory peptide tuftsin with an added stabilizing sequence to resist enzymatic breakdown. It has since been approved as a pharmaceutical in Russia and studied extensively in the anxiolytic and nootropic research literature.
Modern stress rarely announces itself — it shows up as a racing mind at bedtime, a shortened fuse, a body that stays braced even when nothing is technically wrong. Selank research has focused on calming that response without the fog or dependence risk associated with more familiar anti-anxiety compounds.
Published research has documented Selank’s role in modulating GABAergic and serotonergic activity, upregulating brain-derived neurotrophic factor (BDNF) expression, and supporting balanced cytokine and immune signaling as a tuftsin-derived compound. It is among the more thoroughly characterized anxiolytic peptides in the Russian pharmacological literature.